• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• Twitter
• Newsletter

Advertisement

Collaboration › Details

AbbVie–JPMorgan Chase: investor conference, 202301 supply service AbbVie presents at JP Morgan Healthcare Conference 2023

 

	Period	2023-01-10
	Region	San Francisco, CA
	Country	United States (USA)
	Partner, 1st	AbbVie Inc. (NYSE: ABBV)
	Group	AbbVie (Group)
	Partner, 2nd	J.P. Morgan Securities LLC
	Group	JPMorgan Chase (Group)
	Product	J.P. Morgan 41st Annual Healthcare Conference 2023 San Francisco
	Product 2	pharmaceutical
	Person	Gonzalez, Richard A. (Abbott 201110 EVP Global Pharmaceuticals before COO)
	Person 2	Shea, Liz (AbbVie 202301 Investor Relations)

AbbVie Inc.. (1/3/23). "Press Release: AbbVie to Present at the 41st Annual J.P. Morgan Healthcare Conference". North Chicago, IL.

AbbVie (NYSE: ABBV) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023. Richard A. Gonzalez, chairman and chief executive officer, will present at 5:00 p.m. CT.

A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.


About AbbVie

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, and women's health, in addition to products and services across our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.


Contact(s)

Media
Frank Benenati
(224) 688-4169
frank.benenati@abbvie.com

Investors
Liz Shea
(847) 935-2211
liz.shea@abbvie.com

Record changed: 2023-01-08

Advertisement

More documents for AbbVie (Group)

• [1] AbbVie Inc.. (1/3/23). "Press Release: AbbVie to Present at the 41st Annual J.P. Morgan Healthcare Conference". North Chicago, IL....
• [2] AbbVie Inc.. (10/20/22). "Press Release: AbbVie Acquires DJS Antibodies, Further Strengthening Immunology Pipeline". North Chicago, IL....
• [3] Sosei Group Corporation (d/b/a Sosei Heptares). (8/2/22). "Press Release: Sosei Heptares and AbbVie Enter New Multi-target Collaboration to Discover, Develop and Commercialize Novel Medicines Targeting Neurological Diseases". Tokyo & Cambridge....
• [4] AbbVie Inc.. (3/1/22). "Press Release: AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio". North Chicago, IL....
• [5] Abingworth LLP. (9/15/21). "Press Release: Abingworth Strengthens Investment Team with New Appointments in the US and UK". London....
• [6] Mission Therapeutics Ltd.. (8/9/21). "Press Release: Mission and AbbVie Collaboration in Alzheimer’s and Parkinson’s Diseases Reaches Next Milestone- Mission Receives $20 Million Milestone payment". Cambridge....
• [7] Novartis AG. (3/22/21). "Press Release: Novartis Appoints Karen Hale as Chief Legal Officer". Basel....
• [8] Caribou Biosciences, Inc.. (2/10/21). "Press Release: AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products". North Chicago, IL & Berkeley, CA....
• [9] Genmab A/S. (6/10/20). "Press Release: Genmab and AbbVie Announce Broad Oncology Collaboration". Copenhagen & North Chicago, IL....
• [10] Roche. (3/23/20). "Press Release: Roche Announces Venclexta/Venclyxto Combination Improved Overall Survival in People with Previously Untreated Acute Myeloid Leukaemia". Basel....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2023. Made in Germany.